Viabio develops software for modeling and simulating the physical processes involved in 3D bioprinting, specifically focusing on enhancing the viability of bioprinted tissues and organs through AI-driven analysis. The platform addresses the challenge of ensuring the survival of bioprinted constructs by providing real-time adjustments and optimization based on critical construction parameters.
Funding
Funding not disclosed
Founders
Product
Problem
Ensuring the viability of bioprinted tissues and organs is a significant challenge due to the complex physical processes involved in 3D bioprinting. Current methods lack real-time adjustment and optimization capabilities, hindering the efficiency and scalability of bioprinting technology.
Solution
Viabio offers a SaaS platform that models and simulates the physical processes within bioprinted constructs to enhance their viability. The software uses AI and mathematical modeling to analyze critical construction parameters and provide real-time adjustments. By optimizing the design of bioprinted tissues and organs, Viabio's technology aims to improve the efficiency and scalability of 3D bioprinting. The platform focuses on analyzing spheroids, with future plans to study organoids and various 3D bioprinting techniques.
Target Audience
Viabio targets researchers, scientists, and biotech companies involved in 3D bioprinting, tissue engineering, and regenerative medicine.
Features
- Software-as-a-Service (SaaS) platform for modeling physical processes inside printed organic structures
- AI-driven analysis to optimize bioprinted tissue and organ design
- Real-time adjustment of bioprinting processes using computer vision control
- Modeling of bioprinting physics to enhance viability
- Capability to load an STL model composed of spheroids and adjust structure parameters
- Time distribution of cell necrosis score after calculations
- Cloud-based calculations to save user resources and time